ACRV insider transaction filings
Acrivon Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-02. Screen ACRV transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 9 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 9 legs across 8 filings by 7 insiders — 18,754 shares, $39,806 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: sale of 14,036 shares @ $2.21 ($30,969) by Blume-Jensen Peter, filed 2026-08-27.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Blume-Jensen Peter — President and CEO, Director & Masson Kristina — EVP - Business Operations, Director | 2 | — | 3 legs · 15,749 sh · $34,412 | — |
| Levy Adam D. — Chief Financial Officer | 1 | — | 1 leg · 1,142 sh · $1,793 | — |
| Miller Mary — Chief Legal Officer | 2 | — | 2 legs · 758 sh · $1,380 | — |
| Devroe Eric — Chief Operating Officer | 1 | — | 1 leg · 604 sh · $1,214 | — |
| Gamelin Erick — Chief Development Officer | 1 | — | 1 leg · 400 sh · $804 | — |
| Peterson Katharine — Chief Accounting Officer | 1 | — | 1 leg · 101 sh · $203 | — |
| Levin Michaela — Chief Business Officer | 1 | — | — | 2 |
Recent Form 4 filings — Acrivon Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | Levin Michaela — Chief Business Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2026-08-27 | 4 | Blume-Jensen Peter — President and CEO, Director Masson Kristina — EVP - Business Operations, Director | Sale (S): 14,036 @ $2.21 | EDGAR |
| 2026-08-20 | 4 | Gamelin Erick — Chief Development Officer | Sale (S): 400 @ $2.01 | EDGAR |
| 2026-08-20 | 4 | Miller Mary — Chief Legal Officer | Sale (S): 185 @ $2.01 | EDGAR |
| 2026-08-20 | 4 | Peterson Katharine — Chief Accounting Officer | Sale (S): 101 @ $2.01 | EDGAR |
| 2026-08-20 | 4 | Blume-Jensen Peter — President and CEO, Director Masson Kristina — EVP - Business Operations, Director | Sale (S): 1,229 @ $2.01 · Sale (S): 484 @ $2.01 | EDGAR |
| 2026-08-20 | 4 | Devroe Eric — Chief Operating Officer | Sale (S): 604 @ $2.01 | EDGAR |
| 2026-08-06 | 4 | Levy Adam D. — Chief Financial Officer | Sale (S): 1,142 @ $1.57 | EDGAR |
| 2026-07-23 | 4 | Miller Mary — Chief Legal Officer | Sale (S): 573 @ $1.76 | EDGAR |
| 2026-06-22 | 4 | Palani Santhosh — Director | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | DiRocco Derek — Director | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Shacham Sharon — Director | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | BAUM CHARLES M — Director | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | TOMSICEK MICHAEL JOHN — Director | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Magovcevic-Liebisch Ivana — Director | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Blume-Jensen Peter — President and CEO, Director Masson Kristina — EVP - Business Operations, Director | Tax withholding (F): 13,729 @ $1.79 | EDGAR |
| 2026-05-20 | 4 | Palani Santhosh — Director | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2026-05-20 | 4 | DiRocco Derek — Director | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2026-05-20 | 4 | Peterson Katharine — Chief Accounting Officer | Grant/award (A): 14,227 @ $0 | EDGAR |
| 2026-05-20 | 4 | Miller Mary — Chief Legal Officer | Grant/award (A): 49,830 @ $0 | EDGAR |
| 2026-05-20 | 4 | Levy Adam D. — Chief Financial Officer | Grant/award (A): 46,167 @ $0 | EDGAR |
| 2026-05-20 | 4 | Gamelin Erick — Chief Development Officer | Grant/award (A): 38,584 @ $0 | EDGAR |
| 2026-05-20 | 4 | Devroe Eric — Chief Operating Officer | Grant/award (A): 72,981 @ $0 | EDGAR |
| 2026-05-20 | 4 | Blume-Jensen Peter — President and CEO, Director Masson Kristina — EVP - Business Operations, Director | Grant/award (A): 180,095 @ $0 · Grant/award (A): 72,706 @ $0 | EDGAR |
| 2026-05-20 | 4 | Shacham Sharon — Director | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2026-05-20 | 4 | Mirza Mansoor Raza — Chief Medical Officer | Grant/award (A): 38,817 @ $0 | EDGAR |
| 2026-05-20 | 4 | BAUM CHARLES M — Director | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2026-05-20 | 4 | TOMSICEK MICHAEL JOHN — Director | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2026-05-20 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2026-05-20 | 4 | Magovcevic-Liebisch Ivana — Director | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2026-05-18 | 4 | Peterson Katharine — Chief Accounting Officer | Tax withholding (F): 99 @ $1.92 | EDGAR |
| 2026-05-18 | 4 | Miller Mary — Chief Legal Officer | Tax withholding (F): 184 @ $1.92 | EDGAR |
| 2026-05-18 | 4 | Gamelin Erick — Chief Development Officer | Tax withholding (F): 404 @ $1.92 | EDGAR |
| 2026-05-18 | 4 | Devroe Eric — Chief Operating Officer | Tax withholding (F): 613 @ $1.92 | EDGAR |
| 2026-05-18 | 4 | Blume-Jensen Peter — President and CEO, Director Masson Kristina — EVP - Business Operations, Director | Tax withholding (F): 1,253 @ $1.92 · Tax withholding (F): 490 @ $1.92 | EDGAR |
| 2026-04-23 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 3,888,888 @ $1.80 | EDGAR |
| 2026-04-21 | 4 | Miller Mary — Chief Legal Officer | Tax withholding (F): 558 @ $1.78 | EDGAR |
| 2026-03-03 | 4 | Peterson Katharine — Chief Accounting Officer | Grant/award (A): 31,900 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Miller Mary — Chief Legal Officer | Grant/award (A): 129,760 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Levy Adam D. — Chief Financial Officer | Grant/award (A): 132,925 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Gamelin Erick — Chief Development Officer | Grant/award (A): 94,946 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Devroe Eric — Chief Operating Officer | Grant/award (A): 186,728 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Blume-Jensen Peter — President and CEO, Director Masson Kristina — EVP - Business Operations, Director | Grant/award (A): 417,210 (derivative) @ $0 · Grant/award (A): 185,495 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Mirza Mansoor Raza — Chief Medical Officer | Grant/award (A): 174,068 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Blume-Jensen Peter — President and CEO, Director Masson Kristina — EVP - Business Operations, Director | Tax withholding (F): 14,265 @ $1.53 | EDGAR |
| 2026-02-18 | 4 | Miller Mary — Chief Legal Officer | Tax withholding (F): 217 @ $1.63 | EDGAR |
| 2026-02-18 | 4 | Gamelin Erick — Chief Development Officer | Tax withholding (F): 471 @ $1.63 | EDGAR |
| 2026-02-18 | 4 | Devroe Eric — Chief Operating Officer | Tax withholding (F): 723 @ $1.63 | EDGAR |
| 2026-02-18 | 4 | Blume-Jensen Peter — President and CEO, Director Masson Kristina — EVP - Business Operations, Director | Tax withholding (F): 1,302 @ $1.63 · Tax withholding (F): 579 @ $1.63 | EDGAR |
Recent 8-K events — Acrivon Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-02 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-02-27 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-05 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ACRV returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →